Clinical trials: Restenoses, Coronary
Ischemic Heart Disease, Angina Pectoris
Physiology and Residual Ischemia After Percutaneous Coronary Intervention
Despite optimal angiographic result after stent implantation, a number of patients will undergo repeat angiography within 1 year of index procedure.
- Conditions
- Ischemic Heart Disease, Angina Pectoris, Chest Pain, Coronary Artery Disease
- Trial name
- EASY-PRIPCI (NCT04494750)
- Where
- Canada
- Volunteers
- 260 people
- Sponsor
- Laval University
Coronary Artery Disease
Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents
For lesions which develop restenosis after a drug-eluting stent, it is not known which the right strategy to use is, implantation of the same type of DES as the initial one or a DES with a different drug.
- Trial name
- DESIRE-2 (NCT00598715)
- Testing
- Sirolimus eluting stent, Paclitaxel-eluting stent
- Where
- 2 sites in Germany
- Volunteers
- 450 people
- Sponsor
- Deutsches Herzzentrum Muenchen
In-stent Coronary Artery Restenosis
Prognostic Assessment of Different Pattern of Bifurcation Restenosis
The LATINA registry aims at assessing a new classification of bifurcation restenosis in the prediction of major adverse cardiac events in patients who have previously undergone a succesful percutaneous bifurcation intervention.
- Trial name
- LATINA (NCT01411475)
- Testing
- Bifurcation restenosis classification
- Where
- 2 sites in Italy
- Sponsor
- Ospedale Santa Maria Goretti
In-Stent Restenosis
P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses
The aim of the study is to assess the safety and efficacy of the Paclitaxel-eluting PTCA-balloon in the treatment of in-stent restenoses in native coronary arteries with reference diameters between 2.5 mm and 3.5 mm and ≤ 22 mm…
- Trial name
- NCT00393315
- Testing
- paclitaxel coated balloon catheter
- Where
- 10 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital, Saarland
Coronary Artery Disease, Coronary Restenosis
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR
AbsorbISR is a randomized, controlled trial, single center, prospective, not blinded to evaluate two strategies of in stent restenosis treatment: Implantation of drug eluting bioresorbable stent scaffold Absorb® vs.
- Trial name
- AbsorbISR (NCT02474485)
- Testing
- BVS Absorb implantation., DEB Sequent Please inflation., Control coronary angiography.
- Where
- Switzerland
- Volunteers
- 53 people
- Sponsor
- SIS Medical AG
Coronary Artery Bypass, Atherosclerosis
Study of the Xience V Everolimus-eluting Stent in Saphenous Vein Graft Lesions
The specific aim of the SOS-Xience V study is to examine the 12-month incidence of binary angiographic in-stent restenosis after implantation of the Xience V stent in aortocoronary saphenous vein bypass graft lesions.
- Trial name
- SOS-Xience V (NCT00911976)
- Testing
- Xience V coronary stent
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- North Texas Veterans Healthcare System
Diabetes Mellitus, Coronary Restenosis
Clinical and Angiographic Outcomes With Hyperglycemic Control Post PCI
Coronary artery disease is a process that results in "hardening of the arteries". When the arteries that supply blood and oxygen to your heart muscle become clogged or narrowed, a heart attack may result, or you may feel chest…
- Trial name
- NCT00412126
- Testing
- Insulin
- Where
- Canada
- Volunteers
- 240 people
- Sponsor
- Hamilton Health Sciences Corporation
Coronary Artery Disease
Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation
Percutaneous coronary intervention (PCI) with the use of bare metal stents is associated with restenosis in approximately 10% to 50% of cases.
- Trial name
- TOP RACER (NCT01638078)
- Testing
- Thalidomide
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Coronary Disease, Coronary Artery Disease
PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions
PROSPECT is a multi-center prospective registry of Acute Coronary Syndromes (ACS) patients with single or double vessel coronary artery disease.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- NCT00180466
- Where
- 40 sites in United States, Belgium and 10 more
- Volunteers
- 697 people
- Sponsor
- Abbott Medical Devices
Coronary Disease, Coronary Artery Disease
SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)
The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- NCT01171820
- Testing
- TAXUS® Liberté™, XIENCE V® EECSS
- Where
- 28 sites in Austria, France and 9 more
- Volunteers
- 324 people
- Sponsor
- Abbott Medical Devices
Diabetes Mellitus, Type 2, Coronary Restenosis
Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty
The purpose of this clinical research study is determine if patients with diabetes that have undergone previous opening of a heart blockage may have a blockage that is not causing any symptoms that may be detected by imaging with…
- Trial name
- NCT00162357
- Testing
- Technetium Tc99m Sestamibi
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 106 people
- Sponsor
- Lantheus Medical Imaging
In-Stent Coronary Artery Restenosis, Coronary Artery Disease
The PICCOLETO XI A-PREP Study
To compare the angiographic and clinical outcomes of aggressive versus standard balloon preparation during drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR).
- Trial name
- PICCOLETO-XI (NCT07391033)
- Volunteers
- 500 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Myocardial Ischemia, Coronary Artery Stenosis
Safety Study of a Bioresorbable Coronary Stent
To evaluate the safety of a new bioresorbable (non-permanent) stent platform in native coronary arteries.
- Conditions
- Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease
- Trial name
- RESTORE (NCT01262703)
- Testing
- ReZolve Stent
- Where
- Brazil
- Volunteers
- 49 people
- Sponsor
- REVA Medical, Inc.
Coronary Disease, Coronary Artery Disease
To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels
The purpose of this study is to determine the safety and clinical outcomes of the Absorb BVS for daily use in patients with de novo lesions in previously untreated vessels.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ABSORB UK (NCT01977534)
- Testing
- Absorb BVS
- Where
- 24 sites in United Kingdom
- Volunteers
- 1,005 people
- Sponsor
- Abbott Medical Devices
Coronary Restenosis
EGO-COMBO Clinical End-point Extension Study Beyond 36 Months
In this study, the safety and efficacy of COMBO TM stent beyond 36 months are assessed, in particular the occurrence of late stent thrombosis and late loss catch-up (restenosis).
- Trial name
- NCT02263313
- Testing
- EGO-COMBO group
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The University of Hong Kong
Coronary Artery Disease, Coronary Artery Stenosis
Disease Characteristics of IR-CAD: a Case-control Study
The present case-control study is designed to investigate the disease characteristics of IR-CAD by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between 20 patients with IR-CAD…
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease Progression
- Trial name
- NCT06007248
- Testing
- Protocol-defined Examinations
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Coronary Artery Disease, Coronary Artery Stenosis
A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)
To evaluate the safety and efficacy of the Absorb BVS System compared to the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the treatment of subjects with ischemic heart disease caused by up to two de novo native…
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- ABSORB CHINA (NCT01923740)
- Testing
- XIENCE V EECSS, Absorb BVS System
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Abbott Medical Devices
Coronary Disease, Coronary Artery Disease
SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe
The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT V (NCT00402272)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 93 sites in Austria, Belgium and 21 more
- Volunteers
- 2,700 people
- Sponsor
- Abbott Medical Devices
Coronary Restenosis
Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II)
The PACCOCATH ISR II study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in coronary in-stent restenosis.
- Trial name
- NCT00409981
- Testing
- paclitaxel coated balloon catheter (device with drug)
- Where
- 5 sites in Germany
- Volunteers
- 56 people
- Sponsor
- University Hospital, Saarland
Coronary Disease, Coronary Artery Disease
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis
- Trial name
- EXecutive (NCT00531011)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent System, TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
- Where
- 24 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices